IMMUNOHISTOCHEMISTRY, E-CADHERIN

The IHC – E-Cadherin test is an immunohistochemistry-based diagnostic assay used to detect E-Cadherin protein expression in tissue samples. E-Cadherin is a cell adhesion molecule that helps neighboring epithelial cells remain attached to one another, maintaining normal tissue structure and organization.

Loss or abnormal expression of E-Cadherin is associated with several cancers and is particularly important in the diagnosis and classification of breast cancer, especially when differentiating invasive lobular carcinoma from invasive ductal carcinoma. This marker is also used in the evaluation of gastric, ovarian, prostate, and other epithelial tumors.

The IHC E-Cadherin test helps pathologists determine tumor behavior, assess cell adhesion characteristics, and identify specific cancer subtypes. Because changes in E-Cadherin expression are linked to tumor invasion and metastasis, this test provides valuable information for diagnosis and treatment planning.

Benefits of the Test

• Helps diagnose epithelial-origin cancers
• Assists in breast cancer classification
• Differentiates lobular carcinoma from ductal carcinoma
• Supports tumor characterization and staging
• Helps guide treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC E-Cadherin test when evaluating breast tumors and epithelial malignancies. It is commonly used in:

• Diagnosis of invasive lobular breast carcinoma
• Differentiation of ductal and lobular breast cancers
• Evaluation of gastric carcinoma
• Assessment of epithelial tumors
• Investigation of metastatic cancers

E-Cadherin is often used together with markers such as ER, PR, HER2, Ki-67, GATA3, and Cytokeratins to provide a comprehensive pathological evaluation.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or dietary restrictions are needed
• Clinical history and imaging findings may assist interpretation
• Previous pathology reports may help with diagnosis

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing requirements and laboratory workflow.

Who Should Take This Test

• Patients with suspected breast cancer
• Individuals undergoing breast tumor evaluation
• Patients with epithelial tumors requiring classification
• Cases requiring differentiation between lobular and ductal carcinoma
• Oncology patients requiring immunohistochemistry profiling

The IHC E-Cadherin test is an important diagnostic tool in breast pathology and oncology. By evaluating cell adhesion protein expression, it helps clinicians accurately classify tumors and develop personalized treatment strategies.

Clinical Significance

E-Cadherin staining is commonly used in the diagnosis and evaluation of:

• Invasive lobular breast carcinoma
• Invasive ductal breast carcinoma
• Gastric adenocarcinoma
• Ovarian epithelial tumors
• Prostate carcinoma
• Metastatic epithelial cancers

Loss of E-Cadherin expression is a characteristic feature of invasive lobular carcinoma and can help distinguish it from other breast cancer subtypes.